4 Lactobacillus Paracasei Health Benefits

This 2011 randomized placebo-controlled study published in the Clinical & Experimental Allergy tested Lactobacillus paracasei ST11 on 31 adults with pollen allergies over 4-weeks. Groups were given ST11-fermented milk or a placebo drink before being triggered with allergens. The results showed that those who drank the probiotic milk had lower nasal congestion vs the placebo group. Analysis of blood samples also showed an immune response with Interleukin 5 and serum IgG4 lower which both may play a role in allergic rhinitis.

This second randomized, double-blind, placebo-controlled study from 2005 tested Lactobacillus Paracasei 33 (LP33) in 90 participants with house dust mite-triggered rhinitis. Instead of the fermented milk, they were given 5 billion CFU in capsule form twice daily for 30-days. During the participant's clinical visits they filled out a questionnaire scoring their rhinoconjunctivitis symptoms and the conclusion was that versus placebo, there was an improvement in quality of life in the L. Paracasei groups.

Researchers from McMaster University, Ontario, Canada published their paper in September 2004 sharing the efficacy of Lactobacillus paracasei, Lactobacillus johnsonii, Bifidobacterium longum, and Bifidobacterium lactis on mice induced with muscle hypercontractility to simulate Irritable Bowel Syndrome. Lactobacillus Paracasei was said to be the only strain that was able to attenuate muscle hypercontractility potentially because of an immunologic response triggered by Lactobacillus Paracasei.

This 2014 Randomised clinical trial was conducted by the Laboratory of Experimental Pathophysiology, I.R.C.C.S. Saverio de Bellis, National Institute of Digestive Diseases, Castellana Grotte, Bari, Italy. It was published in the Alimentary Pharmacology & Therapeutics peer-reviewed journal.

20 participants with IBS-C were enrolled and split into placebo groups eating either normal or 2 Billion CFU of Lactobacillus Paracasei IMPC 2.1 soaked artichokes twice daily for 15 days. Those who had eaten the probiotic & prebiotic artichokes had improvements in constipation, increased short-chain fatty acid production, and significantly higher propionic acid all when compared to baseline scores.

The efficacy of Lactobacillus paracasei B21060 bacteria taken with, Arabinogalactan & Xilooligosaccharides prebiotic fiber in 52 children with IBS-D and 55 other children also with IBS-D taking a placebo. The study was carried out by researchers from the Department of Paediatrics, University of Naples "Federico II", Italy. The results showed that after just 72 hours of taking the probiotics, the children had a 67% improvement in their acute diarrhea versus 40% in the placebo group. It was also noted that stool consistency improved along with daily stool outputs.

This Danish randomized controlled trial from 2014 tested if Lactobacillus paracasei subsp paracasei L. casei W8 in piglets and postprandially in humans. After 2 weeks of piglets taking the probiotic bacteria had an increase in the proglucagon gene which is significant because they play a role in glucose metabolism. In humans, benefits for glucose and insulin response were also observed but the bacteria did not suppress appetite. The study didn't prove that L. Paracasei could significantly help with weight loss.

Other L. Paracasei studies were carried out on mice and rats with this one showing Lactobacillus paracasei subsp. paracasei NTU 101 decreased body weight in obese rats. Another showedhttps://www.ncbi.nlm.nih.gov/pubmed/24351773 Lactobacillus paracasei ST11 reduced body weight and abdominal fat weight in rats. It's unclear if these results could also translate to humans as well so more human clinical trials are needed to confirm the efficacy of L. Paracasei for weight loss.

In December at the end of 2019 research from Switzerland & France was published in the Frontiers In Nutrition. The study carried out in Vitro looked at the effects of 100 Million CFU Lactobacillus paracasei CNCM I-1518 on two strains of pathogenic Clostridioides difficile bacteria.

The vitro setup created an environment mimicking a proximal colon that had the gut microbiota composition donated from an elderly volunteer since people over the age of 65 are said to be more at risk for C Diff. The L. Paracasei bacteria showed that it modulated an increase of Faecalibacterium probiotic bacteria but this specific Lactobacillus Paracasei had no benefits against C. Diff.